Copyright
©The Author(s) 2023.
World J Gastroenterol. Mar 14, 2023; 29(10): 1614-1626
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1614
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1614
Table 1 The baseline characteristics of included patients (n, %)
Overall | Lenvatinib + TACE + PD-1 | Lenvatinib + TACE | P value | |
Patient characteristics | ||||
Number (n) | 65 | 45 | 20 | |
Age, median (range), yr | 57 (18-79) | 54 (18-79) | 62 (26-75) | 0.0661 |
< 65 | 50 (76.92) | 38 (84.44) | 12 (60.00) | |
≥ 65 | 15 (23.08) | 7 (15.56) | 8 (40.00) | |
Gender | 0.0951 | |||
Female | 8 (12.31) | 3 (6.67) | 5 (25.00) | |
Male | 57 (87.69) | 42 (93.33) | 15 (75.00) | |
ECOG-PS | 0.1541 | |||
0 | 33 (50.77) | 26 (57.78) | 7 (35.00) | |
1 | 32 (49.23) | 19 (42.22) | 13 (65.00) | |
Etiology | 0.0021 | |||
HBV | 54 (83.08) | 42 (93.33) | 12 (60.00) | |
HCV | 4 (6.15) | 2 (4.44) | 2 (10.00) | |
Non-HBV, non-HCV | 7 (10.77) | 1 (2.22) | 6 (30.00) | |
Hepatic cirrhosis | 0.8791 | |||
Yes | 43 (66.15) | 29 (64.44) | 14 (70.00) | |
No | 22 (33.85) | 16 (35.56) | 6 (30.00) | |
AFP | 0.5511 | |||
< 400 | 21 (32.31) | 13 (28.89) | 8 (40.00) | |
≥ 400 | 44 (67.69) | 32 (71.11) | 12 (60.00) | |
Child-Pugh score | 0.0951 | |||
A5 | 48 (73.85) | 30 (66.67) | 18 (90.00) | |
A6 or B7 | 17 (26.15) | 15 (33.33) | 2 (10.00) | |
BCLC stage | 1.0001 | |||
A or B | 16 (24.62) | 11 (24.44) | 5 (25.00) | |
C | 49 (75.38) | 34 (75.56) | 15 (75.00) | |
Tumor characteristics | ||||
Tumor size | 0.0351 | |||
< 7 cm | 25 (38.46) | 13 (28.89) | 12 (60.00) | |
≥ 7 cm | 40 (61.54) | 32 (71.11) | 8 (40.00) | |
Tumor number | 0.2601 | |||
Single | 21 (32.31) | 17 (37.78) | 4 (20.00) | |
Multiple | 44 (67.69) | 28 (62.22) | 16 (80.00) | |
TBS group | 0.1731 | |||
L | 23 (35.38) | 13 (28.89) | 10 (50.00) | |
H | 42 (64.62) | 32 (71.11) | 10 (50.00) | |
Portal vein tumor thrombus | 0.1081 | |||
Presence | 24 (36.92) | 20 (44.44) | 4 (20.00) | |
Absence | 41 (63.08) | 25 (55.56) | 16 (80.00) | |
Extrahepatic metastasis | 0.3761 | |||
Yes | 23 (35.38) | 18 (40.00) | 5 (25.00) | |
No | 42 (64.62) | 27 (60.00) | 15 (75.00) | |
TACE times | 0.2601 | |||
< 3 | 44 (67.69) | 28 (62.22) | 16 (80.00) | |
≥ 3 | 21 (32.31) | 17 (37.78) | 4 (20.00) |
Table 2 Therapeutic efficacy in all patients, n (%)
Table 3 Therapeutic efficacy in patients with stage A or B and stage C, n (%)
BCLC A or B | BCLC C | |||||
Lenvatinib + TACE + PD-1 (n = 11) | Lenvatinib + TACE (n = 5) | P value | Lenvatinib + TACE + PD-1 (n = 34) | Lenvatinib + TACE (n = 15) | P value | |
CR | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||
PR | 8 (72.7) | 1 (20) | 12 (35.3) | 3 (20.0) | ||
SD | 3 (27.3) | 2 (40) | 19 (55.9) | 7 (46.7) | ||
PD | 0 (0) | 2 (40) | 3 (8.8) | 5 (33.3) | ||
ORR | 8 (72.7) | 1 (20) | 0.0772 | 12 (35.3) | 3 (20) | 0.2352 |
DCR | 11(100) | 3 (60) | 0.0832 | 31 (91.2) | 10 (66.7) | 0.0472 |
Table 4 Adverse events, n (%)
AEs | Lenvatinib + TACE + PD-1 | Lenvatinib + TACE | ||
All grades | Grade 3/4 | All grades | Grade 3/4 | |
Decreased appetite | 19 (42.2) | 3 (6.7) | 7 (35.0) | 2 (10.0) |
Elevated AST | 18 (40) | 3 (6.7) | 5 (25.0) | 0 (0) |
Decreased albumin | 18 (40) | 2 (4.4) | 6 (30.0) | 1 (5.0) |
Fatigue | 17 (37.8) | 3 (6.7) | 8 (40.0) | 1 (5.0) |
Diarrhoea | 13 (28.9) | 5 (11.1) | 4 (20.0) | 1 (5.0) |
Hypertension | 13 (28.9) | 3 (6.7) | 3 (15.0) | 0 (0) |
Elevated blood bilirubin | 13 (28.9) | 2 (4.4) | 5 (25.0) | 0 (0) |
Decreased platelet count | 13 (28.9) | 2 (4.4) | 5 (25.0) | 1 (5.0) |
Hypothyroidism | 12 (26.7) | 2 (4.4) | 3 (15.0) | 0 (0) |
Abdominal pain | 11 (24.4) | 2 (4.4) | 4 (20.0) | 1 (5.0) |
Elevated ALT | 11 (24.4) | 2 (4.4) | 4 (20.0) | 0 (0) |
Rash | 8 (17.8) | 2 (4.4) | 2 (10.0) | 0 (0) |
Decreased WBC | 7 (15.6) | 0 (0) | 4 (20.0) | 0 (0) |
Vomiting | 7 (15.6) | 0 (0) | 3 (15.0) | 0 (0) |
Hypocalcemia | 6 (13.3) | 0 (0) | 5 (25.0) | 0 (0) |
Palmar-plantar erythrodysaesthesia | 5 (11.1) | 0 (0) | 1 (5.0) | 0 (0) |
Nausea | 4 (8.9) | 0 (0) | 4 (20.0) | 0 (0) |
Elevated WBC | 4 (8.9) | 0 (0) | 3 (15.0) | 0 (0) |
Gingival bleeding | 4 (8.9) | 0 (0) | 1 (5.0) | 0 (0) |
Gastrointestinal hemorrhage | 4 (8.9) | 1 (2.2) | 0 (0) | 0 (0) |
Decreased weight | 3 (6.7) | 0 (0) | 2 (10.0) | 0 (0) |
Dysphonia | 3 (6.7) | 0 (0) | 2 (10.0) | 0 (0) |
Proteinuria | 1 (2.2) | 1 (2.2) | 1 (5.0) | 0 (0) |
- Citation: Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1614-1626
- URL: https://www.wjgnet.com/1007-9327/full/v29/i10/1614.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i10.1614